|
Home Page
About Us
Investors
Inventors
Portfolio
3DR Laboratories, LLC
AllTranz Inc.
AnosiaVax, Inc.
ApoImmune, Inc.
EndoProtech, Inc.
Eyevation, LLC
ImmunoTheragnostics Incorporated
InnoRem, Inc.
Intrepid Bioinformatics, Inc.
PGxl Laboratories, LLC
Pradama Inc.
RhinoCyte, Inc.
TrackFive Diagnostics, Inc.
ULSD, LLC
Contact Us
Privacy Policy
|
|
|
|
Portfolio - ApoImmune, Inc.
| Incorporated: |
|
June 2001
|
| Contacts: |
|
Steve Gailar, Acting CEO
|
Scientific Founder:
|
|
Haval Shirwan, Ph.D.
|
| Description: |
|
ApoImmune, Inc. is a biotechnology company committed to the development of powerful new therapeutics to treat chronic and acute life-threatening diseases and improve patients' quality of life. ApoImmune is founded on a broad-platform protein-based technology used for immunomodulation - that is - using one's own immune system to treat disease.
ApoImmune's technology platform, licensed from the University of Louisville Research Foundation, is the result of more than a decade of research conducted by co-founder and Chief Scientific Officer Dr. Haval Shirwan. ApoImmune holds an exclusive worldwide license to the technology underlying this research.
ApoImmune completed an institutional financing in 2006, receiving $500K in economic development incentives and continues to develop a lead vaccine product utilizing a $750K Phase I grant from NCI. The company has also been approved for a $1.8M SBIR grant in the current budget, (actual grant amount to be determined upon final SBIR budget).
By 3Q08, ApoImmune had secured more than $3.4M in financing and grants, leading to a successful PreIND meeting 2Q09. The ApoImmune team is currently completing the IND enabling phase.
ApoImmune continues to improve its intellectual property standing, having filed three additional patent applications. Phase I Clinical Trials for its lead product are anticipated to begin in 2009.
|
| Web Site: |
|
http://www.apoimmune.com/ |
|
|
